Synopsis
FDA-Approved Biosimilar Products Biosimilar Name Approval Date Reference Product More Information Lucamzi (ranibizumab-blrz) October 2026 Lucentis (ranibizumab) Zimrixby (rituximab-cdxx) July 2026 Rituxan (rituximab) Garzulys (insulin aspart-fsan) July 2026 Novolog (insulin aspart) Garzulys Information Ranluspec (ranibizumab-hkdz) June 2026 Lucentis (ranibizumab) Ranluspec Information Immgolis and Immgolis Intri (golimumab-sldi) May 2026 Simponi and Simponi Aria (golimumab) I
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
